GridAI Technologies Corp.

GridAI Technologies Corp. is unable, without unreasonable effort or expense, to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Due to a delay in obtaining and compiling information required to be included in the Form 10-Q, the Company requires additional time to finalize its review of the financial information for the quarter ended June 30, 2026. The Company is requesting an extension for the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and currently expects to file the report no later than the fifth calendar day following the prescribed due date

GridAI Technologies Corp. is unable, without unreasonable effort or expense, to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Due to the delay in finalizing and filing the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the Company requires additional time to finalize its review of the financial information for the quarter ended March 31, 2026. The Company is requesting an extension for the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and currently expects to file the report no later than the fifth calendar day following the prescribed due date

We are currently reviewing the accounting treatment and other information related to our recent acquisition of GridAI Corp. Due to the complexity of this matter, we require additional time to ensure that the financial statements are accurately presented in accordance with the relevant accounting standards. As such, we are requesting an extension for filing of our 10-K Annual Report for the year ended December 31, 2025. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, it is anticipated that the Registrant will file its Form 10-K no later than the fifteenth .calendar day following the prescribed due date

We are currently reviewing the accounting treatment of our acquisition of GridAI Corp. Due to the complexity of this matter, we require additional time to ensure that the financial statements are accurately presented in accordance with the relevant accounting standards. As such, we are requesting an extension for filing of our 10-Q Quarterly Report for the quarter ended September 30, 2025. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, it is anticipated that the Registrant will file its Form 10-Q no later than the fifth calendar day following the prescribed due date

We are currently reviewing the accounting treatment of a significant transaction. Due to the complexity of this matter, we require additional time to ensure that the financial statements are accurately presented in accordance with the relevant accounting standards. As such, we are requesting an extension for filing our 10-K SEC 1344 (04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

Entero Therapeutics, Inc. (the “Company”) plans to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) as soon as practicable. As disclosed in the Company’s Current Report on Form 8-K filed with the SEC on August 15, 2024, Forvis Mazars, LLP (“Forvis Mazars”) notified the Company on August 9, 2024, that they would be resigning as the Company’s auditors, effective immediately. The Company is in the process of engaging a new independent registered public accounting firm. As a result, the Company does not currently expect to file its Form 10-Q by the prescribed due date allowed pursuant to Rule 12b-25

First Wave BioPharma, Inc. (the “Company”) plans to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) as soon as practicable and within the five calendar day period provided by Rule 12b-25 for delayed filings. The Company requires additional time to complete the review of its financial statements for the quarter ended March 31, 2022, and the Company cannot, without unreasonable effort or expense, file the Form 10-Q on the original due date. The Company anticipates that it will be able to file the Form 10-Q within the extension period provided under Rule 12b-25

AzurRx BioPharma, Inc. (the “Company”) plans to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) as soon as practicable and within the five calendar day period provided by Rule 12b-25 for delayed filings. The delay is due primarily to the Company’s recent financings and transactions described below. On January 6, 2021, the Company consummated a registered direct offering and private placement of approximately $8.0 million of shares of Series C Preferred Stock and warrants to purchase shares of common stock. On January 8, 2021, the Company issued approximately $2.5 million of shares of Series C Preferred Stock to First Wave Bio, Inc. in connection with the license agreement entered into between the Company and First Wave Bio, Inc. The preferred stock prohibited any conversion of Series C Preferred Stock that would result in the holder owning 20% or more of the Company’s common stock prior to stockholder approval of certain proposals related to the registered direct offering and private placement. The stockholders of the Company approved certain proposals related to the registered direct offering and the private placement on February 24, 2021, and all outstanding shares of Series C Preferred Stock were converted to common stock. As a result of the Company consummating the registered direct offering and private placement, the holders of the Company’s outstanding Series B Preferred Stock became entitled to exercise their exchange right to exchange their Series B Preferred Stock into Series C Preferred Stock and related warrants. During the three month period ended March 31, 2021, holders with an aggregate of approximately $10.1 million stated value of Series B Preferred Stock exercised their exchange right into shares of Series C Preferred Stock and warrants and the shares of Series C Preferred Stock were converted to common stock